Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 7:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 11,433 matching trials from the live ClinicalTrials.gov search.
Conditions
Alzheimer Disease
Interventions
neflamapimod, placebo
Drug · Other
Lead sponsor
EIP Pharma Inc
Industry
Eligibility
55 Years to 85 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
16
States / cities
Long Beach, California • San Diego, California • Santa Ana, California + 13 more
Conditions
Pancreatic Alpha Cell Carcinoma, Pancreatic Beta Islet Cell Carcinoma, Pancreatic Delta Cell Carcinoma, Pancreatic G-cell Carcinoma, Recurrent Islet Cell Carcinoma
Interventions
temozolomide, pazopanib hydrochloride
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
5
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 2 more
Conditions
Hiv
Interventions
Core-g28v2 60mer mRNA Vaccine, eOD-GT8 60mer mRNA Vaccine
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • San Antonio, Texas + 1 more
Conditions
Myelodysplastic Syndromes
Interventions
Imetelstat Sodium, Placebo
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
22
States / cities
Birmingham, Alabama • Tucson, Arizona • Bakersfield, California + 16 more
Conditions
Asthma, Asthma Attack, Asthma Exacerbations
Interventions
Inhaled corticosteroid (ICS), Azithromycin, Asthma Symptom Monitoring Web-based Application
Drug · Other
Lead sponsor
DARTNet Institute
Government
Eligibility
13 Years to 75 Years
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
13
States / cities
Aurora, Colorado • Orlando, Florida • Kansas City, Kansas + 9 more
Conditions
Cytomegalovirus (CMV) Infection
Interventions
Letermovir oral granules, Letermovir tablet, Letermovir intravenous
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
Up to 17 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
11
States / cities
Duarte, California • Orange, California • San Francisco, California + 8 more
Conditions
Acute Anemia
Interventions
SANGUINATE™
Drug
Lead sponsor
Prolong Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
32
States / cities
Birmingham, Alabama • Prescott, Arizona • Baldwin Park, California + 26 more
Conditions
Neoplasms
Interventions
Letetresgene autoleucel, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
10 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
24
States / cities
Duarte, California • Stanford, California • Denver, Colorado + 19 more
Conditions
Diverticulitis
Interventions
Partial Colectomy, Medical Management
Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
29
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 24 more
Terminated Phase 2Phase 3 Interventional Results available

Drug Study of Albuterol to Treat Acute Lung Injury

NCT00434993
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Albuterol Sulfate, Mini-Bronchoalveolar Lavage (BAL), Placebo
Drug · Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
13 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
40
States / cities
Fresno, California • Sacramento, California • San Francisco, California + 19 more
Conditions
Esophageal Stricture
Interventions
GIE Medical ProTractX3 TTS DCB, Control
Combination Product · Other
Lead sponsor
GIE Medical
Industry
Eligibility
22 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
34
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Irvine, California + 29 more
Conditions
HIV Infections, Meningitis
Interventions
Quadrivalent meningococcal conjugate vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 24 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
35
States / cities
Alhambra, California • Long Beach, California • Los Angeles, California + 25 more
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography, Magnetic Resonance Imaging, Bone Scan, Electronic Health Record Review
Procedure · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
BAF312, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
1,651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
52
States / cities
Phoenix, Arizona • Berkeley, California • Los Angeles, California + 45 more
Conditions
Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma
Interventions
XmAb®23104, Yervoy® (ipilimumab)
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
18
States / cities
San Diego, California • Aurora, Colorado • Denver, Colorado + 15 more
Conditions
HIV Infections
Interventions
Ezetimibe
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more
Conditions
Metastatic Cancer, Radiation Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
therapeutic melatonin, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
0 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
215
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more
Conditions
Childhood Obesity
Interventions
Family-based behavioral intervention
Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
7 Years to 11 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Malignant Glioma, Glioblastoma Multiforme, GBM, Anaplastic Astrocytoma, Oligo-Astrocytoma, Gliosarcoma
Interventions
131-I-TM-601, 131I-TM601
Drug
Lead sponsor
TransMolecular
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 14 more
Conditions
Major Depressive Disorder
Interventions
desvenlafaxine succinate sustained-release, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
44
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Arcadia, California + 38 more
Conditions
Fallopian Tube Carcinoma, Infectious Disorder, Neutropenia, Ovarian Carcinosarcoma, Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Interventions
Adjuvant Therapy, Carboplatin, Paclitaxel, Pegfilgrastim
Procedure · Drug · Biological
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
11
States / cities
Orange, California • Iowa City, Iowa • Camden, New Jersey + 6 more
Conditions
Refractory Metastatic Colorectal Cancer, pMMR, MSS
Interventions
RP2, RP3, atezolizumab, bevacizumab
Biological
Lead sponsor
Replimune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Seattle, Washington
Conditions
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
Interventions
fludarabine phosphate, peripheral blood stem cell transplantation, iodine I 131 tositumomab, laboratory biomarker analysis, flow cytometry, polymerase chain reaction
Drug · Procedure · Radiation + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
60 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
gefitinib
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
95
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 63 more